Recovery from the hurricane, which devastated four Medtronic facilities located on Puerto Rico, is projected to cost $50m to $60m, according to a preliminary second-quarter earnings estimate from the firm. Last month, the company suggested costs could be as high as $250m.
Medtronic lowered its estimate of what Hurricane Maria might cost the company by almost $200m in a preliminary second quarter earnings report issued Nov. 8.
The company estimates costs of $55m to $65m, with the majority of the impact coming from the firm's minimally invasive and restorative therapies groups. In its original estimate on Oct....
Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.
Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
